Friday, July 10, 2026

Drug profile · INN

insulin degludec / insulin aspart

insulin degludec / insulin aspart (RYZODEG) is an FDA-listed pharmaceutical active ingredient.

PMDA: approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — insulin degludec / insulin aspart
Class
Route
Patents
0
Programs
2
Data quality
0.78

Quick answer

insulin degludec / insulin aspart (RYZODEG) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN insulin degludec / insulin aspart
Brand RYZODEG

Approval history

Authority Status Date
PMDA approved

Pipeline programs

  1. Insulin degludec/insulin aspart Phase 3 · Novo Nordisk A/S · Diabetes
  2. NN1535-8377 Phase 3 · NovoThirteen · Type 2 diabetes

Frequently asked questions

What is insulin degludec / insulin aspart?

insulin degludec / insulin aspart (RYZODEG) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for insulin degludec / insulin aspart?

RYZODEG is a marketed brand name for insulin degludec / insulin aspart. Check FDA Drugs@FDA for the current US label holder and prescribing information.